Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Product sales	$ 589,947	$ 761,664	$ 1,171,195	$ 1,489,297
License fee and other revenues	25,403		36,228
Research and development	55,754	241,127	194,559	585,492
Total revenues	671,104	1,002,791	1,401,982	2,074,789
Costs and Expenses:
Costs of goods sold	64,519	68,983	122,783	145,269
Research and development	14,261,676	10,364,850	27,174,806	19,756,867
Sales and marketing	386,696	174,795	530,217	403,432
General and administrative	1,655,841	1,856,036	3,380,135	5,675,228
Total costs and expenses	16,368,732	12,464,664	31,207,941	25,980,796
Operating loss	(15,697,628)	(11,461,873)	(29,805,959)	(23,906,007)
Interest expense	(1,369,956)		(2,739,911)
Interest and other income	83,762	11,216	175,720	36,288
Foreign currency transaction gain (loss), net	6,950	11,899	(3,511)	162
Loss before income tax benefit (expense)	(16,976,872)	(11,438,758)	(32,373,661)	(23,869,557)
Income tax benefit (expense)	3,204,250	(26,892)	3,185,000	(38,855)
Net loss	(13,772,622)	(11,465,650)	(29,188,661)	(23,908,412)
Less: Net loss attributable to noncontrolling interest	(26,572)	(30,415)	(48,789)	(62,757)
Net loss attributable to Immunomedics, Inc. stockholders	$ (13,746,050)	$ (11,435,235)	$ (29,139,872)	$ (23,845,655)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted)	$ (0.15)	$ (0.12)	$ (0.31)	$ (0.26)
Weighted average shares used to calculate loss per common share, (basic and diluted)	94,664,758	93,157,279	94,630,292	93,127,741
Other comprehensive loss, net of tax:
Foreign currency translation adjustments	$ (54,739)	$ (79,703)	$ (37,271)	$ (257,833)
Unrealized loss on securities available for sale securities	(112,964)	(5,999)	(79,267)	(10,451)
Other comprehensive loss	(167,703)	(85,702)	(116,538)	(268,284)
Comprehensive loss	(13,940,325)	(11,551,352)	(29,305,199)	(24,176,696)
Less comprehensive loss attributable to noncontrolling interest	(26,572)	(30,415)	(48,789)	(62,757)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	$ (13,913,753)	$ (11,520,937)	$ (29,256,410)	$ (24,113,939)